



**Press release**

March 10, 2026

## **Notice of Annual General Meeting 2026**

**March 25, 2026**

**The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on Wednesday 25 March 2026 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.**

### **Agenda**

1. The Board of Directors’ report on the Company’s activities in the preceding financial year
2. Presentation and approval of the annual report
3. Resolution on appropriation of profit or covering of loss as recorded in the annual report
4. Election of members to the Board of Directors
5. Election of auditor
6. Proposed resolutions, if any, from the Board of Directors and/or the shareholders of the Company

**Press release**

March 10, 2026

**Complete proposals**

**1. The Board of Directors' report on the Company's activities in the past financial year**

The Board of Directors proposes that the general meeting takes note of the Board of Directors' report on the Company's activities in the past financial year

**2. Presentation and adoption of the annual report**

The Board of Directors proposes that the annual report for the financial year 2025 is adopted.

**3. Resolution on appropriation of profit or covering of loss as recorded in annual report**

The Board of Directors proposes that the result for 2025 is carried forward to next year in accordance with the annual report for 2025.

**4. Election of members to the Board of Directors**

The Board of Directors proposes re-election of the following board members:

- Kirsten Aarup Drejer
- Andreas Kjær
- Ulrich Krasilnikoff

As Lars Trolle and Charlotte Vedel wish to resign from the Board of Directors, a proposal was made for the election of Marcel Reichen and Colin Hayward as new board members.

Marcel Reichen's and Colin Hayward's CV are annexed to the AGM notice.

**5. Election of auditor**

The Board of Directors proposes re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 33771231, as auditor of the Company.

**6. Proposed resolutions from the Board of Directors or the shareholders**



**Press release**  
March 10, 2026

\*\*\*\*\*

**Press release**

March 10, 2026

**Majority requirements**

Adoption of the proposals set out in items 2–5 of the agenda are subject to a simple majority of votes, cf. section 105 of the Danish Companies Act.

**Share capital and voting rights**

On the date of this press release, the nominal share capital of Curasight is DKK 2.417.610,20 divided into shares of a nominal value of DKK 0.05 each. Each share of nominally DKK 0.05 carries one vote at the general meeting (48,352,204 votes in total).

**Participation and voting rights**

All shareholders holding shares in the Company on the date of registration have a right to attend and vote at the Annual General Meeting. The date of registration is Wednesday 18 March 2026.

The number of shares held by each shareholder at the date of registration is based on information recorded in the Company's shareholders' register at the expiry of the registration date as well as any notification received by the Company for registration but not yet entered in the shareholders' register at the expiry of the registration date.

**Registration and notice of attendance**

A shareholder wishing to attend the Annual General Meeting is requested to notify the Company of the shareholder's attendance no later than on Friday 20 March 2026 at 23.59 (CET). Attendance can be notified by completing, signing, and returning a dated registration form (notification of attendance) by email to [uk@curasight.com](mailto:uk@curasight.com). Registration forms can be found at [www.curasight.com/investor/general-meetings](http://www.curasight.com/investor/general-meetings).

A shareholder or its proxy holder wishing to register an advisor for attending the Annual General Meeting must state the name and email address of the advisor, when submitting the notification of attendance.

**Press release**

March 10, 2026

**Proxy**

Shareholders may attend the Annual General Meeting by proxy to the Board of Directors or a third party. Proxies can be granted by completing, signing, and returning a dated proxy form. Proxy forms can be found at [www.curasight.com/investor/general-meetings](http://www.curasight.com/investor/general-meetings).

Proxies must be received by the Company no later than Friday 20 March 2026 at 23.59 (CET) as a scanned copy by email to [uk@curasight.com](mailto:uk@curasight.com).

Proxies can be revoked by the shareholder at any time. Revocation must be in writing by e-mail to [uk@curasight.com](mailto:uk@curasight.com) and include proper identification of the shareholder revoking the proxy.

**Postal vote**

Shareholders may vote by post with respect to the agenda items of the Annual General Meeting. Postal votes can be submitted by completing, signing, and returning a dated postal vote form. Postal vote forms can be found at [www.curasight.com/investor/general-meetings](http://www.curasight.com/investor/general-meetings).

Postal votes must be received by the Company no later than Monday 23 March 2026 at 23.59 (CET) as scanned copy by email to [uk@curasight.com](mailto:uk@curasight.com).

Postal votes cannot be revoked.

**Information at the Company's website**

Further information on the Annual General Meeting and the following information and documents will be available at the Company's website [www.curasight.com/investor/general-meetings](http://www.curasight.com/investor/general-meetings) until and including the date of the Annual General Meeting:

1. The notice convening the Annual General Meeting, including the agenda and complete proposals
2. The total number of shares and voting rights as of the date of the notice
3. The annual report for 2025
4. The documents to be submitted to the Annual General Meeting
5. Proxy/postal voting forms applicable to the Annual General Meeting

**Press release**

March 10, 2026

**Questions from shareholders**

Any shareholder can ask questions to the Board of Directors and the Executive Management about the annual report for 2025, the Company in general or the agenda items prior to the Annual General Meeting. Such questions can be submitted by email to [uk@curasight.com](mailto:uk@curasight.com).

Questions from shareholders submitted prior to the Annual General Meeting will, as far as possible, be answered in writing prior to the Annual General Meeting or presented by the chairman of the Annual General Meeting and answered at the Annual General Meeting, provided that the shareholder concerned attend the Annual General Meeting.

Moreover, shareholders can ask questions at the Annual General Meeting. If a question cannot be answered at the Annual General Meeting, the answer will be published on the Company's website, [www.curasight.com](http://www.curasight.com), no later than two weeks after the Annual General Meeting.

**Personal data**

Prompted by requirements set out in the Danish Companies Act, the Company processes personal information about its shareholders as part of the administration of the company's register of shareholders and other communications. The following information is processed: Name, address, contact information, VP account number, shareholding and participation in events.

**Language**

The Annual General Meeting will be conducted in Danish, and all representatives of the Company and the chairman of the Annual General Meeting will make their presentations and answer questions in Danish.

\*\*\*\*\*

**The Board of Directors**

March 10, 2026



**Press release**

March 10, 2026

**About Curasight A/S**

Curasight is advancing uTREAT<sup>®</sup>, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT<sup>®</sup> targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company's theranostic platform also includes uTRACE<sup>®</sup>, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT<sup>®</sup>. uTRACE<sup>®</sup> supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO

E-mail: [uk@curasight.com](mailto:uk@curasight.com)

[www.curasight.com](http://www.curasight.com)